Episode Details

FDA just approved Gilead’s new once-daily HIV pill, Bixlenvo — the first single-tablet option for adults with suppressed HIV who can’t use existing one-pill treatments. Combining bictegravir and groundbreaking lenacapavir, it simplifies regimens for those managing drug resistance or side effects from older meds, especially as they age. Two major studies confirmed its effectiveness in maintaining viral suppression and showed it’s generally well-tolerated. This marks a key step in Gilead’s mission to offer flexible, patient-centered HIV treatment options — from pills to injections — empowering people to choose what works best for their lives.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/13070209ef1489d5